Overview

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open-label, 2-arm Phase 2 study to evaluate the efficacy and safety of Fluzoparib with Apatinib versus Fluzoparib alone, as treatment, in relapsed ovarian cancer patients. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 2 portion of the study.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib